The present invention relates to processes, and process intermediates useful in the preparation of (1aS,5aS)-2-(4-oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid ((S)-1-hydroxymethyl-2,2-dimethyl-propyl)-amide (Compound 1) and crystalline forms thereof. The compound (1aS,5aS)-2-(4-oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid ((S)-1-hydroxymethyl-2,2-dimethyl-propyl)-amide has been identified as a modulator of the cannabinoid 2 (CB2) receptor and useful in the treatment of CB2 receptor-mediated disorders, for example, pain, disorders of the immune system (such as, autoimmune disorders, type 1 hypersensitivity and allergic response, conditions associated with CNS inflammation, conditions associated with vascular inflammation, and other disorders associated with aberrant or unwanted immune response), bone and joint diseases (such as, osteoporosis and arthritis), eye disease, cough, cancer, and regenerative medicine. The present invention further provides pharmaceutical compositions comprising Compound 1 and the use of the pharmaceutical compositions for the treatment of CB2 receptor-mediated disorders.Cette invention concerne des procédés, et des intermédiaires de procédés utiles dans la préparation de ((S)-1-hydroxyméthyl-2,2-diméthyl-propyl)-amide dacide (1aS,5aS)-2-(4-oxy-pyrazin-2-yl)-1a,2,5,5a-tétrahydro-1H-2,3-diaza-cyclopropa[a]pentalène-4-carboxylique (Composé 1) et de formes cristallines de celui-ci. Le composé de ((S)-1-hydroxyméthyl-2,2-diméthyl-propyl)-amide dacide (1aS,5aS)-2-(4-oxy-pyrazin-2-yl)-1a,2,5,5a-tétrahydro-1H-2,3-diaza-cyclopropa[a]pentalène-4-carboxylique a été identifié comme un modulateur du récepteur 2 des cannabinoïdes (CB2), utile dans le traitement des troubles médiés par le récepteur CB2, par exemple, la douleur, les troubles du système immunitaire (tels que les troubles auto-immuns, lhypersensibilité de type 1 et la réponse allergique, les affec
